- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 01.06. | T-CURX Acquires Pantherna Therapeutics to Boost Clinical Validation of In-Vivo CAR-T Therapies | 1 | Contract Pharma | ||
| 01.06. | LNP-Delivery im Fokus: T-CURX übernimmt Pantherna | 1 | transkript.de | ||
| 14.05. | Curanex Pharmaceuticals Inc: Curanex Reports First Quarter 2026 Business Progress as Phyto-N Advances Toward Planned FDA Submission | 190 | GlobeNewswire (Europe) | Completed GMP manufacturing and toxicology milestones supporting planned Q4 2026 IND submission for ulcerative colitis Expanded pipeline strategy to include cancer cachexia, a serious cancer-associated... ► Artikel lesen | |
| CURANEX PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 14.05. | Curanex Pharmaceuticals Inc - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 07.05. | Curanex Pharmaceuticals Inc - 8-K, Current Report | - | SEC Filings | ||
| 08.04. | Curanex Pharmaceuticals Inc: Curanex Highlights Five Additional Patient Cases Further Supporting the Potential of Its Lead Candidate in Cancer Cachexia, Advanced Cancer Supportive Care and Severe Systemic Decline | 236 | GlobeNewswire (Europe) | Expanded case series includes advanced thymic carcinoma, small cell lung cancer, pancreatic cancer, end-stage liver cirrhosis, and end-stage renal disease According to patient accounts, multiple critically... ► Artikel lesen | |
| 08.04. | EXCLUSIVE: Penny Stock Curanex Expands Cachexia Focus Backed By Patient Recovery Narratives | 1 | Benzinga.com | ||
| 06.04. | Curanex Pharmaceuticals Inc: Curanex Highlights Patient Case Study Supporting Potential of Phyto-N in Cancer Cachexia and Advanced Cancer Supportive Care | 1 | GlobeNewswire (USA) | ||
| 06.04. | EXCLUSIVE: Curanex Highlights Case Study Supporting Cachexia Focus In Oncology Strategy | 1 | Benzinga.com | ||
| 02.04. | Curanex Pharmaceuticals Inc: Curanex Expands Its Drug Development Pipeline to Include Cancer Cachexia, Representing a Multi-Billion-Dollar Market Opportunity and Important Step In The Company's Evolution Into a Broader Therapeutics Development ... | 334 | GlobeNewswire (Europe) | Company expands strategic focus into one of oncology's most urgent supportive-care challenges Jericho, New York, April 02, 2026 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals, Inc. (Nasdaq: CURX) ("Curanex"... ► Artikel lesen | |
| 02.04. | EXCLUSIVE: Curanex Pipeline Expansion Signals Push Beyond Inflammation, Metabolic Diseases | 2 | Benzinga.com | ||
| 02.04. | Curanex Pharmaceuticals Inc - 8-K, Current Report | 2 | SEC Filings | ||
| 30.03. | Curanex Pharmaceuticals Inc: Curanex Provides Business Update in Connection with 2025 Annual Report as Phyto-N Advances Toward Planned IND Submission | 379 | GlobeNewswire (Europe) | Company advances manufacturing, toxicology, patent and regulatory milestones while building a broader pharmaceutical development platform Jericho, New York, March 30, 2026 (GLOBE NEWSWIRE) -- Curanex... ► Artikel lesen | |
| 30.03. | Curanex Pharmaceuticals Inc - 10-K, Annual Report | - | SEC Filings | ||
| 18.03. | Curanex Pharmaceuticals Inc: Curanex Achieves Key Preclinical Milestone with Favorable Toxicology Profile at Maximum Dose, Advancing Toward IND Submission | 190 | GlobeNewswire (Europe) | Phyto-N 28-Day Repeat-Dose Study in Rats and Dogs Shows No Findings of Toxicological Significance at Maximum Feasible Dose, Enabling Advancement to GLP Toxicology Program Jericho, New York, March... ► Artikel lesen | |
| 12.03. | Curanex stärkt wissenschaftlichen Beirat vor wichtigem Zulassungsantrag | - | Investing.com Deutsch | ||
| 12.03. | Curanex adds two advisors to scientific board ahead of IND filing | 1 | Investing.com | ||
| 12.03. | Curanex Pharmaceuticals Inc: Curanex Expands Scientific Advisory Board With Two Distinguished Researchers | 1 | GlobeNewswire (USA) | ||
| 11.03. | Curanex adds two pharmaceutical veterans to advisory board | 2 | Investing.com | ||
| 11.03. | Curanex Pharmaceuticals Inc: Curanex Appoints Two Veteran Industry Leaders to Scientific Advisory Board | 1 | GlobeNewswire (USA) |
1 2 Weiter >>
29 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CANOPY GROWTH | 0,829 | -0,79 % | Canopy Growth-Aktie: Alles nur noch Rauch? | Die Canopy Growth-Aktie setzte auch zum Wochenbeginn ihre leichte Talfahrt fort und fiel am gestrigen Montag unter die so wichtige Kursmarke von 1 US$. Können die Quartalszahlen dem kanadischen Cannabisproduzenten... ► Artikel lesen | |
| EYEPOINT | 12,200 | +1,67 % | EyePoint Aktionäre genehmigen Incentive-Plan und wählen Direktoren | ||
| FILANA THERAPEUTICS | 1,084 | +0,18 % | Filana Therapeutics, Inc.: Filana Therapeutics Reports Q1 2026 Financial Results and Business Update | AUSTIN, Texas, May 07, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, "Filana Therapeutics", the "Company"), a biotechnology company currently focused on developing therapies for... ► Artikel lesen | |
| COMPASS PATHWAYS | 11,200 | +0,90 % | Psychedelika-Boom 2.0: Während US-Riesen mit Milliarden bewertet werden, liefert dieser australische Spezialist bereits Daten | ||
| CORBUS PHARMACEUTICALS | 7,410 | +1,65 % | Corbus Pharmaceuticals Holdings, Inc. - S-8, Securities to be offered to employees in employee benefit plans | ||
| DARE BIOSCIENCE | 2,130 | -1,84 % | Dare Bioscience, Inc. - 8-K, Current Report | ||
| CITIUS PHARMACEUTICALS | 0,579 | +5,97 % | Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update | $5.6 Million in net revenue for the first half of fiscal 2026 from ongoing launch of LYMPHIR®
Citius Pharma raised $5 million in a registered direct offering; Citius... ► Artikel lesen | |
| ELEDON PHARMACEUTICALS | 3,460 | +3,59 % | Leerink raises Eledon Pharmaceuticals price target on trial data | ||
| CENTESSA PHARMACEUTICALS | 34,400 | -1,15 % | Centessa Pharmaceuticals plc: Acquisition of Centessa by Lilly Approved by the High Court of Justice of England and Wales | BOSTON and LONDON, June 22, 2026 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage company developing a new class of medicines for the treatment of excessive daytime... ► Artikel lesen | |
| EXICURE | 2,180 | +9,00 % | Exicure, Inc.: Exicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement | WILMINGTON, Del., June 10, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR) (the "Company") today announced that it received a notification letter from the Listing Qualifications Department of... ► Artikel lesen | |
| COSMOS HEALTH | 0,189 | +2,72 % | Cosmos Health Inc.: Cosmos Health Builds Contract Manufacturing Orderbook to Over 25 Million Units; Division Positioned to Generate Over $10 Million in Recurring Annual Profit | Cumulative orderbook of over 25 million units secured through wholly owned subsidiary Cana Laboratories across multiple EU and international partners.Multi-year agreements extending up to 10 years provide... ► Artikel lesen | |
| CHAMPIONS ONCOLOGY | 5,350 | 0,00 % | Champions Oncology, Inc.: Champions Oncology to Present New Data on Predicting Response and Resistance at AACR 2026 | Eight studies demonstrate how clinically relevant models and integrated data can reduce translational risk and guide development decisions HACKENSACK, NJ / ACCESS Newswire / April 9, 2026 / Champions... ► Artikel lesen | |
| CHINA SXT PHARMACEUTICALS | 2,270 | +1,79 % | China SXT Pharmaceuticals, Inc. Announces Share Re-classification | TAIZHOU, China, March 23, 2026 (GLOBE NEWSWIRE) -- China SXT Pharmaceutics, Inc. (Nasdaq: SXTC) (the "Company" or "SXTC"), a specialty pharmaceutical company focusing on the research, development... ► Artikel lesen | |
| CUMBERLAND PHARMACEUTICALS | 5,660 | -1,05 % | Cumberland Pharmaceuticals Inc.: Cumberland Pharmaceuticals Reports Q1 2026 Financial Results & Company Update | Enters into Strategic Transaction, unlocking $100 million in value
Sharpens focus on Orphan Drug candidates to address unmet medical needs
NASHVILLE, Tenn., May... ► Artikel lesen | |
| CDT EQUITY | 1,560 | +52,94 % | CDT Equity's Sarborg stake valued at $127.5M after fundraise |
Das Unternehmen CURANEX PHARMACEUTICALS INC kann der Branche Pharma zugeordnet werden. Die relative Kursveränderung beträgt aktuell +2,89 % bei einem Aktienkurs von 0,288 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CURANEX PHARMACEUTICALS INC finden Sie auf Wallstreet Online.